ArticleCell reports. Medicine2024
In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAF
Abstract read
In one paragraph
Article in Cell reports. Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Polyploid cancer cells surviving cisplatin reallocate central carbon sources to fuel antioxidant metabolism for survival.Molecular metabolism · 2026Article
- Genetic mutations governing ferroptosis sensitivity and resistance: a precision approach to cancer therapy.Cell death & disease · 2026Review
- Plasticity, signaling, and metabolic rewiring in melanoma persister cells.Communications biology · 2026Review
- MXD4 enhances resistance to KRAS G12C-targeted therapy in lung adenocarcinoma by suppressing ACSL4-mediated ferroptosis.Respiratory research · 2026Article
- A bibliometric and visualization analysis of global trends and emerging themes in acetylation research for lung cancer.Discover oncology · 2026Article
- Uncovering a novel treatment strategy: sodium butyrate overcomes cisplatin resistance in the oral squamous cell carcinoma by inducing ferroptosis.Journal of experimental & clinical cancer research : CR · 2026Article
- A succinylation-related prognostic model for predicting lung adenocarcinoma prognosis and guiding immunotherapy.Clinical proteomics · 2026Article
- FSP1 and histone deacetylases suppress cancer persister cell ferroptosis.Science advances · 2026Article
- Targeting tumor transition windows.Exploration of targeted anti-tumor therapy · 2026Review
- Harnessing transcriptomics for discovery of natural products to overcome acquired cancer resistance.Archives of pharmacal research · 2026Review
- Pharmacological targeting of HDAC/BET pathway enhances 5-FU efficacy in esophageal squamous cancer cells.Archives of pharmacal research · 2025Article
- Drug-tolerant persister cells in cancer: bridging the gaps between bench and bedside.Nature communications · 2025Review
- The Emerging Roles of Metabolic Reprogramming in Non-Small Cell Lung Cancer Progression.Frontiers in bioscience (Landmark edition) · 2025Review
- Cx43 enhances response to BRAF/MEK inhibitors by reducing DNA repair capacity.Nature communications · 2025Article
- Prevalence, genetic variations and clinical outcomes of BRAF-V600 mutated advanced NSCLC in China: a retrospective real-world multi-centre study.EBioMedicine · 2025Article
- Exploring the Mechanism of Ferroptosis Induction by Sappanone A in Cancer: Insights into the Mitochondrial Dysfunction Mediated by NRF2/xCT/GPX4 Axis.International journal of biological sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Marie-Julie NokinUniversity of Bordeaux, INSERM U1218, ACTION Laboratory, IECB, 33600 Pessac, France; Laboratory of Biology of Tumor and Development (LBTD), GIGA-Cancer, University of Liege, 4000 Liege, Belgium. Electronic address: mjnokin@uliege.be.
Elodie DarboBordeaux Institute of Oncology (BRIC), INSERM U1312, University of Bordeaux, 33000 Bordeaux, France.
Elodie RichardBordeaux Institute of Oncology (BRIC), INSERM U1312, University of Bordeaux, 33000 Bordeaux, France.
Sonia San JoséUniversity of Bordeaux, INSERM U1218, ACTION Laboratory, IECB, 33600 Pessac, France; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, 37007 Salamanca, Spain.
Sergio de HitaUniversity of Bordeaux, INSERM U1218, ACTION Laboratory, IECB, 33600 Pessac, France; Bordeaux Institute of Oncology (BRIC), INSERM U1312, University of Bordeaux, 33000 Bordeaux, France; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, 37007 Salamanca, Spain.
Valérie Prouzet-MauleonBordeaux Institute of Oncology (BRIC), INSERM U1312, University of Bordeaux, 33000 Bordeaux, France; CRISP'edit, TBMCore, University of Bordeaux, CNRS UAR 3427, INSERM US05, 33000 Bordeaux, France.
Béatrice TurcqBordeaux Institute of Oncology (BRIC), INSERM U1312, University of Bordeaux, 33000 Bordeaux, France; CRISP'edit, TBMCore, University of Bordeaux, CNRS UAR 3427, INSERM US05, 33000 Bordeaux, France.
Laura GerardelliLaboratory of Biology of Tumor and Development (LBTD), GIGA-Cancer, University of Liege, 4000 Liege, Belgium.
Rebekah CrakeLaboratory of Biology of Tumor and Development (LBTD), GIGA-Cancer, University of Liege, 4000 Liege, Belgium.
Valérie VelascoDepartment of Biopathology, Institut Bergonié, 33076 Bordeaux, France.
Benjamin KoopmanschDepartment of Human Genetics, University Hospital Center of Liege, 4000 Liege, Belgium.
Frederic LambertDepartment of Human Genetics, University Hospital Center of Liege, 4000 Liege, Belgium.
Jenny Y XueDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Ben SangDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Julie HorneLaboratory of Pharmaceutical Analytical Chemistry, CIRM, University of Liege, 4000 Liege, Belgium.
Eric ZiemonsLaboratory of Pharmaceutical Analytical Chemistry, CIRM, University of Liege, 4000 Liege, Belgium.
Alberto VillanuevaChemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO); Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet del Llobregat, 08908 Barcelona, Spain.
Arnaud BlommeLaboratory of Cancer Signaling, GIGA-Stem Cells, University of Liege, 4000 Liege, Belgium.
Michael HerfsLaboratory of Experimental Pathology, GIGA-Cancer, University of Liege, 4000 Liege, Belgium.
Didier CataldoLaboratory of Biology of Tumor and Development (LBTD), GIGA-Cancer, University of Liege, 4000 Liege, Belgium.
Olivier CalvayracCancer Research Centre of Toulouse, INSERM UMR1037, CNRS UMR5071, 31100 Toulouse, France.
Paolo PorporatoDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, 10126 Torino, Italy.
Ernest NadalMolecular Mechanisms of Cancer Program, Department of Medical Oncology, Catalan Institute of Oncology (ICO), Preclinical and Experimental Research in Thoracic Tumors (PReTT) Group, Oncobell Program, IDIBELL, L'Hospitalet del Llobregat, 08908 Barcelona, Spain.
Piro LitoDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Pasi A JänneDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Biagio RicciutiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Mark M AwadDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Chiara AmbrogioDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, 10126 Torino, Italy. Electronic address: chiara.ambrogio@unito.it.
David SantamaríaUniversity of Bordeaux, INSERM U1218, ACTION Laboratory, IECB, 33600 Pessac, France; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, 37007 Salamanca, Spain. Electronic address: d.santamaria@usal.es.
Bolero Consortium
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Michael Jason de la Cruz · 1985 to 2026
$347.4MNCI NIH HHS P30 CA008748
Abstract
The current targeted therapy for BRAF
Indexed as
Adenocarcinoma of LungDrug Resistance, NeoplasmHistone Deacetylase InhibitorsLung NeoplasmsPhospholipid Hydroperoxide Glutathione PeroxidaseProto-Oncogene Proteins B-rafAnimalsCell Line, TumorFerroptosisHumansImidazolesLipid PeroxidationMiceMutationOxidative StressOximesBRAF protein, humandabrafenibHistone Deacetylase InhibitorsImidazolesOximesPhospholipid Hydroperoxide Glutathione PeroxidaseProto-Oncogene Proteins B-rafPyridonesPyrimidinonestrametinibBRAF oncogeneferroptosisGPX4 inhibitionHDAC inhibitionlung adenocarcinomapersister cellstargeted therapy
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.